CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) — SalioGen Therapeutics, a privately held biotechnology company developing the Gene Coding approach to genetic medicine, announced today the formation of an Executive Advisory Board (EAB) led by John Maraganore, Ph.D., Mark McClellan, M.D., Ph.D. and Andrew Lo, Ph.D. The EAB will work closely with the executive management team in building SalioGen’s sustainable and multidisciplinary strategy and guiding the company as it advances its Gene Coding platform through multiple therapeutic areas. SalioGen Therapeutics has launched Gene CodingTM, a genetic medicine platform, to develop durable, broadly applicable genetic medicines, using its Exact DNA Integration TechnologyTM (EDIT) platform.